Identification of Caveolae-Associated Protein 4 Autoantibodies as a Biomarker of Immune-Mediated Rippling Muscle Disease in Adults

Rippling muscle disease is a rare condition where muscles produce visible wave-like contractions when tapped or stretched. The condition has two forms — one inherited (caused by mutations in the CAV3 or CAVIN1 genes) and one acquired in adulthood, called immune-mediated rippling muscle disease (iRMD). The acquired form responds to immune-suppressing treatment, suggesting the immune system is attacking muscle, but until this study no specific autoantibody had ever been identified to confirm the diagnosis or track the disease.

The Mayo Clinic group (Dubey and colleagues) used phage immunoprecipitation sequencing — an unbiased method that displays the entire human proteome on bacteriophage particles and then captures whatever the patient’s antibodies bind — to screen sera from 10 patients with iRMD. In 8 of those 10 patients, the antibodies bound a single protein: caveolae-associated protein 4, also called cavin-4. The same antibody was absent in 123 healthy controls and in 118 patients with other neuromuscular or autoimmune diseases, including myasthenia gravis. Muscle biopsies from antibody-positive patients showed depletion of cavin-4 in 55–91% of muscle fibers, mirroring the patchy loss of caveolin-3 already known to characterize iRMD on histology.

The finding gives clinicians a blood test to support a diagnosis that previously required muscle biopsy plus exclusion of inherited mutations, and it implicates cavin-4 itself in the disease mechanism. Cavin-4 IgG converts adult-onset iRMD from a label applied after ruling out CAV3/CAVIN1 mutations into an antibody-defined nosological entity — the same kind of rewrite that aquaporin-4 IgG produced for neuromyelitis optica and MuSK IgG produced for seronegative myasthenia gravis — letting clinicians separate inherited rippling muscle disease (which will not respond to immunotherapy) from iRMD (which often does) without committing the patient to muscle biopsy plus a multi-gene caveolinopathy panel as the only diagnostic path.